About the journal
ESMO Open is an open-access journal published by Elsevier in United Kingdom, publishing in english. It is listed in DOAJ and MEDLINE according to the sources read. Declared publication charge: 4,310 USD. Declared review time at DOAJ: 20 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2059-7029
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 4,310 USD
- Articles in DOAJ
- 258
- Declared review time
- 20 weeks
- Declared peer-review model
- peer_review
- Official website
- https://www.sciencedirect.com/journal/esmo-open
Index listings
- DOAJ · 2018-08-03
- MEDLINE · 1990-01-01
- Indexing
- DOAJ · MEDLINE
- APC
- 4,310 USD
- Declared review time (DOAJ)
- 20 weeks
- Actual review time (measured)
- 112 days received→accepted — computed from PubMed (n=98)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
258
Most recent article
6 years ago
Average review time (journal-declared via DOAJ)
20weeks
Works in OpenAlex
7974
Last recorded publication year
2026
h-index
95
i10-index
1158
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2018-08-03
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPMCPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 17%
- ORCID iDs in current deposits
- 13%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity4
- Alternate titles
- ESMO open cancer horizonsEuropean Society for Medical Oncology open
- Source type
- journal
- NLM unique ID (PubMed)
- 101690685
- Society affiliations
- European Society for Medical Oncology
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Breast Cancer Treatment Studies
Show all subjects (50)
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Lung Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Ovarian cancer diagnosis and treatment
- Radiomics and Machine Learning in Medical Imaging
- Radiomics and Machine Learning in Medical Imaging
- Sarcoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Genetic factors in colorectal cancer
- BRCA gene mutations in cancer
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- BRCA gene mutations in cancer
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- CAR-T cell therapy research
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Cancer survivorship and care
- Cancer survivorship and care
Keywords (DOAJ)
- oncology
- cancer
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ